Assertio (NASDAQ:ASRT) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Assertio (NASDAQ:ASRT) released its quarterly earnings results on Wednesday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06), Zacks reports. Assertio had a positive return on equity of 3.79% and a negative net margin of 54.46%. Assertio updated its FY 2025 guidance to EPS.

Assertio Trading Up 0.7 %

Shares of ASRT traded up $0.01 during trading hours on Wednesday, hitting $0.78. 278,982 shares of the stock traded hands, compared to its average volume of 379,384. The firm has a market capitalization of $74.34 million, a PE ratio of -1.07, a price-to-earnings-growth ratio of 3.25 and a beta of 0.81. Assertio has a 1-year low of $0.73 and a 1-year high of $1.80. The company has a current ratio of 2.01, a quick ratio of 1.57 and a debt-to-equity ratio of 0.30. The business has a fifty day moving average of $0.82 and a 200-day moving average of $0.97.

Analysts Set New Price Targets

Several brokerages have recently commented on ASRT. StockNews.com upgraded Assertio from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Assertio in a research report on Monday, December 16th.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.